Chrysoeriol

Name: Chrysoeriol
Brand: MedChemExpress
SKU: HY-121471
Rating: 4.5 (1 reviews)

Cat. No.: HY-121471 Purity: 99.97%: FAQs
Data Sheet SDS COA Handling Instructions

Molarity Calculator

Chrysoeriol is a kind of natural yellow ash, which can be used for heating plants Coronopus didymus. Chrysoeriol suppresses the JAK2/STAT3, IκB/p65, and NF-κB pathways, and has strong anti-inflammatory activity.

For research use only. We do not sell to patients.

Chrysoeriol Chemical Structure

CAS No. : 491-71-4

Size	Price	Stock	Quantity
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO ready for reconstitution	USD 92	In-stock	Estimated Time of Arrival: December 31
Solution
10 mM * 1 mL in DMSO	USD 92	In-stock	Estimated Time of Arrival: December 31
Solid
1 mg	USD 50	In-stock	Estimated Time of Arrival: December 31
5 mg	USD 140	In-stock	Estimated Time of Arrival: December 31
10 mg	USD 230	In-stock	Estimated Time of Arrival: December 31
25 mg	USD 460	In-stock	Estimated Time of Arrival: December 31
50 mg		Get quote
100 mg		Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 publication(s) in Google Scholar

Other Forms of Chrysoeriol:

Chrysoeriol (Standard) Get quote

1 Publications Citing Use of MCE Chrysoeriol

•FOOD BIOPROD PROCESS. 2023 Feb 11.

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

Biological Activity
Purity & Documentation
References
Customer Review

Description

Cellular Effect

Cell Line	Type	Value	Description	References
BXPC-3	GI₅₀	2.6 μg/mL Compound: 5	Cytotoxicity against human BxPC3 cells after 48 hrs by SRB assay Cytotoxicity against human BxPC3 cells after 48 hrs by SRB assay	[PMID: 12608861]
DU-145	GI₅₀	1.1 μg/mL Compound: 5	Cytotoxicity against human DU145 cells after 48 hrs by SRB assay Cytotoxicity against human DU145 cells after 48 hrs by SRB assay	[PMID: 12608861]
KM-20L2	GI₅₀	2.5 μg/mL Compound: 5	Cytotoxicity against human KM20L2 cells after 48 hrs by SRB assay Cytotoxicity against human KM20L2 cells after 48 hrs by SRB assay	[PMID: 12608861]
MCF7	GI₅₀	3.1 μg/mL Compound: 5	Cytotoxicity against human MCF7 cells after 48 hrs by SRB assay Cytotoxicity against human MCF7 cells after 48 hrs by SRB assay	[PMID: 12608861]
Monocyte	IC₅₀	2.6 μM Compound: chrysoeriol	Inhibition of procoagulant activity in monocyte from human blood assessed as counteraction of IL1-induced tissue factor expression after 18 hrs Inhibition of procoagulant activity in monocyte from human blood assessed as counteraction of IL1-induced tissue factor expression after 18 hrs	[PMID: 8882428]
Monocyte	IC₅₀	22 μM Compound: Chrysoeriol	Inhibition of TNFalpha expression in LPS-stimulated human monocytes treated 30 mins before LPS challenge measured after 14 hrs by ELISA Inhibition of TNFalpha expression in LPS-stimulated human monocytes treated 30 mins before LPS challenge measured after 14 hrs by ELISA	[PMID: 10096854]
NCI-H460	GI₅₀	2.1 μg/mL Compound: 5	Cytotoxicity against human NCI-H460 cells after 48 hrs by SRB assay Cytotoxicity against human NCI-H460 cells after 48 hrs by SRB assay	[PMID: 12608861]
Neutrophil	IC₅₀	0.4 μM Compound: 4f, Chrysoeriol	Inhibition of oxidative burst in PMA-stimulated human neutrophils assessed as inhibition of HOCl-induced oxidation of APF after 6 mins by fluorescence assay Inhibition of oxidative burst in PMA-stimulated human neutrophils assessed as inhibition of HOCl-induced oxidation of APF after 6 mins by fluorescence assay	[PMID: 23871908]
Neutrophil	IC₅₀	2.8 μM Compound: 4f, Chrysoeriol	Inhibition of oxidative burst in PMA-stimulated human neutrophils assessed as inhibition of ROS-induced luminol oxidation incubated for 5 mins prior to PMA challenge by chemiluminescence assay Inhibition of oxidative burst in PMA-stimulated human neutrophils assessed as inhibition of ROS-induced luminol oxidation incubated for 5 mins prior to PMA challenge by chemiluminescence assay	[PMID: 23871908]
Neutrophil	IC₅₀	7.1 μM Compound: 4f, Chrysoeriol	Inhibition of oxidative burst in PMA-stimulated human neutrophils assessed as inhibition of superoxide anion radical-induced lucigenin oxidation incubated for 5 mins prior to PMA challenge by chemiluminescence assay Inhibition of oxidative burst in PMA-stimulated human neutrophils assessed as inhibition of superoxide anion radical-induced lucigenin oxidation incubated for 5 mins prior to PMA challenge by chemiluminescence assay	[PMID: 23871908]
Neutrophil	IC₅₀	8.6 μM Compound: 4f, Chrysoeriol	Inhibition of oxidative burst in PMA-stimulated human neutrophils assessed as inhibition of H2O2-induced oxidation of amplex red incubated for 5 mins prior to PMA challenge by fluorescence assay Inhibition of oxidative burst in PMA-stimulated human neutrophils assessed as inhibition of H2O2-induced oxidation of amplex red incubated for 5 mins prior to PMA challenge by fluorescence assay	[PMID: 23871908]
P388	GI₅₀	4 μg/mL Compound: 5	Cytotoxicity against mouse P388 cells after 48 hrs by SRB assay Cytotoxicity against mouse P388 cells after 48 hrs by SRB assay	[PMID: 12608861]
Platelet	IC₅₀	27.14 μM Compound: 5	Anti-platelet activity in rat platelet rich plasma assessed as inhibition of ADP and calcium-induced platelet aggregation incubated at 37 degC for 10 mins and measured 30 mins after ADP and calcium addition Anti-platelet activity in rat platelet rich plasma assessed as inhibition of ADP and calcium-induced platelet aggregation incubated at 37 degC for 10 mins and measured 30 mins after ADP and calcium addition	[PMID: 26096681]
RAW264.7	IC₅₀	0.24 μM Compound: 7	Inhibition of NO production in LPS-stimulated mouse RAW264.7 cells pre-incubated for 2 hrs before LPS stimulation for 24 hrs by Griess assay method Inhibition of NO production in LPS-stimulated mouse RAW264.7 cells pre-incubated for 2 hrs before LPS stimulation for 24 hrs by Griess assay method	[PMID: 25176187]
RAW264.7	IC₅₀	14.2 μM Compound: 7	Antiinflammatory activity against mouse RAW264.7 cells assessed as inhibition of LPS-induced nitrite accumulation after 24 hrs by Griess reagent method Antiinflammatory activity against mouse RAW264.7 cells assessed as inhibition of LPS-induced nitrite accumulation after 24 hrs by Griess reagent method	[PMID: 19778086]
SF-268	GI₅₀	1.7 μg/mL Compound: 5	Cytotoxicity against human SF268 cells after 48 hrs by SRB assay Cytotoxicity against human SF268 cells after 48 hrs by SRB assay	[PMID: 12608861]

In Vitro

Chrysoeriol (5 μM, 10 μM or 20 μM; 24 h) exert a neuroprotective effect in the MPP^--triggered cytotoxicity and apoptosis in SH-SY5Y cells^[2].
Chrysoeriol (20 μM; 24 h) inhibits the production of NO and PGE2 in LPS-stimulated RAW 264.7 cells^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Chrysoeriol (1 mg/ear; external application) improves ear edema induced by 12-O-tetradecanoylphorbol-13-acetate (TPA) in mice, and inhibits the JAK2/STAT3 and IκB/p65 NF-κB pathways to improve inflammation^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Molecular Weight

300.26

Formula

C₁₆H₁₂O₆

CAS No.

491-71-4

Appearance

Solid

Color

Light yellow to yellow

SMILES

O=C1C=C(C2=CC=C(O)C(OC)=C2)OC3=CC(O)=CC(O)=C13

Structure Classification

Initial Source

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

4°C, protect from light

*In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Solvent & Solubility

In Vitro:

DMSO : 100 mg/mL (333.04 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	3.3304 mL	16.6522 mL	33.3045 mL
5 mM	0.6661 mL	3.3304 mL	6.6609 mL
10 mM	0.3330 mL	1.6652 mL	3.3304 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (8.33 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: 2.5 mg/mL (8.33 mM); Suspended solution; Need ultrasonic

This protocol yields a suspended solution of 2.5 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil
Solubility: ≥ 2.5 mg/mL (8.33 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

DMSO +

Tween-80 +

Saline

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Calculation results:

Working solution concentration: mg/mL

Method for preparing stock solution: mg drug dissolved in μL DMSO (Stock solution concentration: mg/mL).

*In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).

Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.

If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.

Purity & Documentation

Purity: 99.97%

Select Batch:

Data Sheet (275 KB) SDS (393 KB)

COA (248 KB) HNMR (244 KB) RP-HPLC (267 KB) LCMS (93 KB)

Handling Instructions (2659 KB)

References

[1]. Beena Mishra, et al. Effect of O-glycosilation on the Antioxidant Activity and Free Radical Reactions of a Plant Flavonoid, Chrysoeriol. Bioorg Med Chem. 2003 Jul 3;11(13):2677-85. [Content Brief]

[2]. Limboonreung T, et al. Chrysoeriol mediates mitochondrial protection via PI3K/Akt pathway in MPP+ treated SH-SY5Y cells. Neurosci Lett. 2020 Jan 1;714:134545. [Content Brief]

[3]. Wu JY, et al. Chrysoeriol ameliorates TPA-induced acute skin inflammation in mice and inhibits NF-κB and STAT3 pathways. Phytomedicine. 2020 Mar;68:153173. [Content Brief]

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	3.3304 mL	16.6522 mL	33.3045 mL	83.2612 mL
	5 mM	0.6661 mL	3.3304 mL	6.6609 mL	16.6522 mL
	10 mM	0.3330 mL	1.6652 mL	3.3304 mL	8.3261 mL
	15 mM	0.2220 mL	1.1101 mL	2.2203 mL	5.5507 mL
	20 mM	0.1665 mL	0.8326 mL	1.6652 mL	4.1631 mL
	25 mM	0.1332 mL	0.6661 mL	1.3322 mL	3.3304 mL
	30 mM	0.1110 mL	0.5551 mL	1.1101 mL	2.7754 mL
	40 mM	0.0833 mL	0.4163 mL	0.8326 mL	2.0815 mL
	50 mM	0.0666 mL	0.3330 mL	0.6661 mL	1.6652 mL
	60 mM	0.0555 mL	0.2775 mL	0.5551 mL	1.3877 mL
	80 mM	0.0416 mL	0.2082 mL	0.4163 mL	1.0408 mL
	100 mM	0.0333 mL	0.1665 mL	0.3330 mL	0.8326 mL

Chrysoeriol Related Classifications

Metabolic Disease

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Chrysoeriol491-71-4Endogenous MetaboliteInhibitorinhibitorinhibit

Please select a local distributor ナミキ商事株式会社コスモ・バイオ株式会社
Product Name			Salutation
Applicant Name *			Email Address *
Phone Number *			Organization Name *
Department *			Requested quantity *
Country or Region *
Remarks

Product Name			Lot #
Applicant Name *			Email Address *
Phone Number			Department *
Organization Name *			Country or Region *
Remarks

Name
Email *

	Sorry, but the email address you supplied was invalid.

Chrysoeriol

Customer Review

Other Forms of Chrysoeriol:

Chrysoeriol Related Antibodies

1 Publications Citing Use of MCE Chrysoeriol

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

Biological Activity

Purity & Documentation

References

Customer Review

Chrysoeriol Related Antibodies

Molarity Calculator

Dilution Calculator

Complete Stock Solution Preparation Table

Chrysoeriol Related Classifications

Keywords:

Your Recently Viewed Products:

Customer Review

Request for HNMR Report

SAFETY DATA SHEET (SDS)

Request for HNMR Report